HRP20181623T1 - Modulatori x receptora jetre (lxr) za liječenje bolesti, poremećaja i stanja kože - Google Patents

Modulatori x receptora jetre (lxr) za liječenje bolesti, poremećaja i stanja kože

Info

Publication number
HRP20181623T1
HRP20181623T1 HRP20181623TT HRP20181623T HRP20181623T1 HR P20181623 T1 HRP20181623 T1 HR P20181623T1 HR P20181623T T HRP20181623T T HR P20181623TT HR P20181623 T HRP20181623 T HR P20181623T HR P20181623 T1 HRP20181623 T1 HR P20181623T1
Authority
HR
Croatia
Prior art keywords
lxr
modulators
disorders
liver
receptor
Prior art date
Application number
HRP20181623TT
Other languages
English (en)
Croatian (hr)
Inventor
Raju Mohan
Original Assignee
Ralexar Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ralexar Therapeutics, Inc. filed Critical Ralexar Therapeutics, Inc.
Publication of HRP20181623T1 publication Critical patent/HRP20181623T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HRP20181623TT 2012-03-02 2018-10-09 Modulatori x receptora jetre (lxr) za liječenje bolesti, poremećaja i stanja kože HRP20181623T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606160P 2012-03-02 2012-03-02
PCT/US2013/028438 WO2013130892A1 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
EP13754329.4A EP2820013B9 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Publications (1)

Publication Number Publication Date
HRP20181623T1 true HRP20181623T1 (hr) 2018-12-14

Family

ID=49083313

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181623TT HRP20181623T1 (hr) 2012-03-02 2018-10-09 Modulatori x receptora jetre (lxr) za liječenje bolesti, poremećaja i stanja kože

Country Status (25)

Country Link
US (5) US8987318B2 (zh)
EP (2) EP3441390A1 (zh)
JP (2) JP6378630B2 (zh)
KR (1) KR102112879B1 (zh)
CN (1) CN104284893B (zh)
AU (1) AU2013225840B2 (zh)
BR (1) BR112014021515A2 (zh)
CA (1) CA2866113C (zh)
CY (1) CY1120742T1 (zh)
DK (1) DK2820013T3 (zh)
ES (1) ES2691079T3 (zh)
HK (1) HK1206030A1 (zh)
HR (1) HRP20181623T1 (zh)
HU (1) HUE040231T2 (zh)
IL (1) IL234413B (zh)
LT (1) LT2820013T (zh)
MX (1) MX361349B (zh)
NZ (1) NZ629636A (zh)
PL (1) PL2820013T3 (zh)
PT (1) PT2820013T (zh)
RS (1) RS57863B9 (zh)
SG (2) SG10201607345YA (zh)
SI (1) SI2820013T1 (zh)
TR (1) TR201815013T4 (zh)
WO (1) WO2013130892A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866113C (en) 2012-03-02 2020-05-12 Alexar Therapeutics, Inc. Pyrazolyl derivatives as liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
WO2014152738A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
CN104151300B (zh) * 2013-05-15 2018-07-13 中国医学科学院医药生物技术研究所 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途
BR112016004904B1 (pt) 2013-09-04 2023-01-24 Ellora Therapeutics, Inc. Compostos moduladores de receptor x do fígado (lxr), seu uso e composição farmaceutica compreendendo os mesmos
US9981913B2 (en) 2013-09-04 2018-05-29 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
WO2017115319A2 (en) 2015-12-30 2017-07-06 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
CN114126618A (zh) 2019-07-15 2022-03-01 诺华股份有限公司 用肝脏x受体激动剂治疗睑板腺功能障碍的方法
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1199771A (en) * 1915-07-01 1916-10-03 Bates Valve Bag Co Wire-twisting machine.
DE60107449T2 (de) 2000-09-18 2005-12-08 Glaxo Group Ltd., Greenford Substituierte aminopropoxyarylderivate als lxr agonisten
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003099769A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Anilino liver x-receptor modulators
BR0311282A (pt) 2002-05-24 2005-04-19 Pharmacia Corp Moduladores sulfona de receptor-x do fìgado
US7265131B2 (en) 2002-12-20 2007-09-04 Exelixis, Inc. Isoquinolinone derivatives and their use as therapeutic agents
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−4(3h)−オン化合物
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
EP1773781A2 (en) 2004-08-03 2007-04-18 Wyeth Indazoles useful in treating cardiovascular diseases
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
SG162803A1 (en) * 2005-06-27 2010-07-29 Exelixis Inc Imidazole based lxr modulators
DE602006016313D1 (de) 2005-09-16 2010-09-30 Arrow Therapeutics Ltd Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
CN101309915A (zh) 2005-11-14 2008-11-19 Irm责任有限公司 作为lxr调节剂的化合物和组合物
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
JP5399262B2 (ja) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Lxrおよびfxrのモジュレーター
US8338437B2 (en) * 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
CA2685002A1 (en) 2007-05-18 2009-02-12 Wyeth Quinazoline compounds
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
AU2008288537B2 (en) 2007-08-13 2011-03-24 F. Hoffmann-La Roche Ag Novel piperazine amide derivatives
US20110034526A1 (en) 2007-12-21 2011-02-10 Wyeth Llc Benzimidazole Compounds
CA2710452A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-a] pyridine compounds
US20120015988A1 (en) * 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
JP2012508250A (ja) 2008-11-07 2012-04-05 ワイス・エルエルシー キノキサリン系のlxrモジュレーター
WO2010059627A1 (en) 2008-11-19 2010-05-27 Wyeth Llc Polar quinazolines as liver x receptors ( lxrs ) modulators
AU2009330233A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
CA2753313A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
LT2435410T (lt) 2009-05-28 2017-04-10 Exelixis Patent Company Llc Lxr moduliatoriai
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
JPWO2012020820A1 (ja) * 2010-08-11 2013-10-28 大正製薬株式会社 ヘテロアリール−ピラゾール誘導体
AU2011293201B2 (en) * 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CA2866113C (en) 2012-03-02 2020-05-12 Alexar Therapeutics, Inc. Pyrazolyl derivatives as liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
EP2882496B1 (en) 2012-08-13 2019-10-09 The Rockefeller University Treatment and diagnosis of melanoma
US9981913B2 (en) 2013-09-04 2018-05-29 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators
BR112016004904B1 (pt) 2013-09-04 2023-01-24 Ellora Therapeutics, Inc. Compostos moduladores de receptor x do fígado (lxr), seu uso e composição farmaceutica compreendendo os mesmos

Also Published As

Publication number Publication date
HK1206030A1 (zh) 2015-12-31
JP2015512883A (ja) 2015-04-30
JP6378630B2 (ja) 2018-08-22
CN104284893A (zh) 2015-01-14
WO2013130892A1 (en) 2013-09-06
EP3441390A1 (en) 2019-02-13
TR201815013T4 (tr) 2018-11-21
EP2820013A4 (en) 2015-11-11
CA2866113A1 (en) 2013-09-06
CY1120742T1 (el) 2019-12-11
IL234413B (en) 2018-05-31
MX2014010537A (es) 2015-03-09
EP2820013B1 (en) 2018-07-11
RS57863B9 (sr) 2019-10-31
AU2013225840A1 (en) 2014-09-18
AU2013225840B2 (en) 2017-11-23
SI2820013T1 (sl) 2018-11-30
US20210101895A1 (en) 2021-04-08
EP2820013A1 (en) 2015-01-07
US20180370959A1 (en) 2018-12-27
LT2820013T (lt) 2018-10-25
CN104284893B (zh) 2017-04-19
NZ629636A (en) 2017-02-24
PL2820013T3 (pl) 2019-01-31
US20170334897A1 (en) 2017-11-23
US9637481B2 (en) 2017-05-02
HUE040231T2 (hu) 2019-02-28
JP6800922B2 (ja) 2020-12-16
ES2691079T9 (es) 2019-02-08
US8987318B2 (en) 2015-03-24
KR102112879B1 (ko) 2020-05-19
RS57863B1 (sr) 2018-12-31
JP2018184467A (ja) 2018-11-22
US20150045399A1 (en) 2015-02-12
US20150152094A1 (en) 2015-06-04
ES2691079T3 (es) 2018-11-23
PT2820013T (pt) 2018-10-25
SG10201607345YA (en) 2016-11-29
KR20140146089A (ko) 2014-12-24
DK2820013T3 (en) 2018-10-29
CA2866113C (en) 2020-05-12
EP2820013B9 (en) 2019-01-09
BR112014021515A2 (pt) 2018-03-13
SG11201405378VA (en) 2014-09-26
MX361349B (es) 2018-12-04

Similar Documents

Publication Publication Date Title
HRP20181623T1 (hr) Modulatori x receptora jetre (lxr) za liječenje bolesti, poremećaja i stanja kože
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
HK1210968A1 (zh) 用於眼部疾病和病症的組合物和治療
HK1198909A1 (zh) 用於治療肝臟疾病和障礙的組合物和方法
IL232334A0 (en) Modulators of the G protein-coupled mas receptor and the treatment of related disorders
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
HK1201826A1 (zh) 用作卵泡刺激素調節劑的苯甲酰胺衍生物
HK1219224A1 (zh) 角結膜病症的治療劑
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
EP2723325A4 (en) NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
IL245511A0 (en) Compositions and methods for treating viral diseases with 4pde modulators
AU2012904982A0 (en) Device for treating respiratory disorders
AU2012900788A0 (en) Combination treatment for rheumatic disorders